• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Competition in pharmaceuticals: more product- than price-oriented?

作者信息

Garattini Livio, Padula Anna

机构信息

IRCCS Institute for Pharmacological Research "Mario Negri", 24020, Ranica, Italy.

出版信息

Eur J Health Econ. 2018 Jan;19(1):1-4. doi: 10.1007/s10198-017-0932-4.

DOI:10.1007/s10198-017-0932-4
PMID:28993950
Abstract
摘要

相似文献

1
Competition in pharmaceuticals: more product- than price-oriented?制药行业的竞争：更多以产品而非价格为导向？
Eur J Health Econ. 2018 Jan;19(1):1-4. doi: 10.1007/s10198-017-0932-4.
2
Do manufacturers of brand-name drugs engage in price competition? An analysis of introductory prices.品牌药制造商是否参与价格竞争？对初始价格的分析。
CMAJ. 2006 Apr 11;174(8):1120-1. doi: 10.1503/cmaj.051687.
3
The impact of generic substitution on price competition in Finland.仿制药替代对芬兰价格竞争的影响。
Eur J Health Econ. 2008 May;9(2):185-91. doi: 10.1007/s10198-007-0059-0. Epub 2007 May 17.
4
Pharmacies take uniform price demands to court.多家药店就统一价格要求提起诉讼。
J Am Health Policy. 1994 Jul-Aug;4(4):24-7.
5
Competition and the Reference Pricing Scheme for pharmaceuticals.药品竞争与参考定价机制。
J Health Econ. 2011 Dec;30(6):1137-49. doi: 10.1016/j.jhealeco.2011.08.010. Epub 2011 Sep 3.
6
Competition Commission identifies issues for further consideration.
Vet Rec. 2002 Apr 20;150(16):494-6.
7
The Contribution Of New Product Entry Versus Existing Product Inflation In The Rising Costs Of Drugs.新药上市与现有药品涨价对药品成本上升的贡献。
Health Aff (Millwood). 2019 Jan;38(1):76-83. doi: 10.1377/hlthaff.2018.05147.
8
The London Agreement and the future of parallel imports.《伦敦协定》与平行进口的未来。
Nat Biotechnol. 2008 Aug;26(8):877-9. doi: 10.1038/nbt0808-877.
9
The demise of the blockbuster?重磅炸弹药物的衰落？
N Engl J Med. 2007 Mar 29;356(13):1292-3. doi: 10.1056/NEJMp078020.
10
Who's really raising drug prices?究竟是谁在真正抬高药价？
Time. 1999 Mar 8;153(9):46-8.

引用本文的文献

1
The Utilization, Reimbursement, and Cost of Targeted Therapies for Duchenne Muscular Dystrophy (DMD) in US Medicaid Programs: A Descriptive Trend Analysis from 2017 to 2022.
Pharmaceut Med. 2025 Nov;39(6):445-452. doi: 10.1007/s40290-025-00587-6. Epub 2025 Sep 20.
2
Worldwide Research Trends and Regional Differences in the Development of Precision Medicine Under Data-Driven Approach: A Bibliometric Analysis.数据驱动方法下精准医学发展的全球研究趋势与区域差异：一项文献计量分析
J Multidiscip Healthc. 2024 Nov 15;17:5259-5275. doi: 10.2147/JMDH.S482543. eCollection 2024.
3
Is greater generic competition also linked to lower drug prices in South Korea?在韩国，更大程度的仿制药竞争也与更低的药品价格有关联吗？

本文引用的文献

1
Between pharmaceutical patents and European patients: is a compromise still possible?在药品专利和欧洲患者之间：是否还有可能达成妥协？
Expert Opin Ther Pat. 2017 Oct;27(10):1073-1076. doi: 10.1080/13543776.2017.1350648. Epub 2017 Jul 10.
2
Use of Generics-A Critical Cost Containment Measure for All Healthcare Professionals in Europe?通用药物的使用——欧洲所有医疗专业人员控制成本的关键措施？
Pharmaceuticals (Basel). 2010 Aug 5;3(8):2470-2494. doi: 10.3390/ph3082470.
3
European Medicines Agency: leave the UK but remain the same.欧洲药品管理局：离开英国但保持不变。
Health Econ Rev. 2020 Sep 15;10(1):30. doi: 10.1186/s13561-020-00289-6.
4
Marketing and Pricing Strategies of Blockbuster Drugs in the South Korean Market: A 15-Year Retrospective Cohort Study for Choline Alfoscerate.韩国市场重磅药物的营销与定价策略：一项关于阿法骨化醇胆碱的15年回顾性队列研究
Front Pharmacol. 2020 Mar 6;11:232. doi: 10.3389/fphar.2020.00232. eCollection 2020.
5
Precision medicine and monoclonal antibodies: breach of promise?精准医学与单克隆抗体：承诺破灭？
Croat Med J. 2019 Jun 13;60(3):284-289. doi: 10.3325/cmj.2019.60.284.
6
Conflict of interest disclosure: striking a balance?利益冲突披露：寻求平衡？
Eur J Health Econ. 2019 Jul;20(5):633-636. doi: 10.1007/s10198-018-1028-5.
7
Pharmaceutical pricing conundrum: time to get rid of it?药品定价难题：是时候解决它了吗？
Eur J Health Econ. 2018 Nov;19(8):1035-1038. doi: 10.1007/s10198-018-0995-x.
J R Soc Med. 2016 Sep;109(9):324-5. doi: 10.1177/0141076816663559.
4
Pharmaceutical Price Schemes in Europe: Time for a 'Continental' One?
Pharmacoeconomics. 2016 May;34(5):423-6. doi: 10.1007/s40273-015-0377-5.
5
After thalidomide - do we have the right balance between public health and intellectual property.沙利度胺事件之后——我们在公共卫生与知识产权之间实现了恰当的平衡吗？
Rev Recent Clin Trials. 2015;10(1):15-8. doi: 10.2174/1574887110666150430145520.
6
From adaptive licensing to adaptive pathways: delivering a flexible life-span approach to bring new drugs to patients.从适应性许可到适应性途径：采用灵活的全生命周期方法将新药带给患者。
Clin Pharmacol Ther. 2015 Mar;97(3):234-46. doi: 10.1002/cpt.59. Epub 2015 Feb 4.
7
Biosimilar versus generic drugs: same but different?生物类似药与仿制药：相同却又不同？
Appl Health Econ Health Policy. 2015 Apr;13(2):125-7. doi: 10.1007/s40258-015-0154-9.
8
Patenting the life sciences at the European Patent Office.在欧洲专利局为生命科学申请专利。
Cold Spring Harb Perspect Med. 2014 Oct 23;4(12):a020792. doi: 10.1101/cshperspect.a020792.
9
What is value in health care?医疗保健中的价值是什么？
N Engl J Med. 2010 Dec 23;363(26):2477-81. doi: 10.1056/NEJMp1011024. Epub 2010 Dec 8.
10
Modeling in pharmacoeconomic studies: funding sources and outcomes.药物经济学研究中的模型构建：资金来源与结果。
Int J Technol Assess Health Care. 2010 Jul;26(3):330-3. doi: 10.1017/S0266462310000322.